NEW YORK, NY / ACCESSWIRE / August 2, 2022 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.

APPS Shareholders Click Here: https://www.zlk.com/pslra-1/digital-turbine-inc-loss-submission-form?prid=30494&wire=1
VRCA Shareholders Click Here: https://www.zlk.com/pslra-1/verrica-pharmaceuticals-inc-loss-submission-form?prid=30494&wire=1
OM Shareholders Click Here: https://www.zlk.com/pslra-1/outset-medical-inc-information-request-form?prid=30494&wire=1

* ADDITIONAL INFORMATION BELOW *

Digital Turbine, Inc. (NASDAQ:APPS)

APPS Lawsuit on behalf of: investors who purchased February 26, 2021 - May 31, 2022
Lead Plaintiff Deadline : August 5, 2022
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/digital-turbine-inc-loss-submission-form?prid=30494&wire=1

According to the filed complaint, during the class period, Digital Turbine, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) the Company's recent acquisitions, AdColony and Fyber, act as agents in certain of their respective product lines; (2) as a result, revenues for those product lines must be reported net of license fees and revenue share, rather than on a gross basis; (3) the Company's internal control over financial reporting as to revenue recognition was deficient; and (4) as a result of the foregoing, the Company's net revenues was overstated throughout fiscal 2022; and (5) as a result of the foregoing, defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Verrica Pharmaceuticals, Inc. (NASDAQ:VRCA)

VRCA Lawsuit on behalf of: investors who purchased May 28, 2021 - May 24, 2022
Lead Plaintiff Deadline : August 5, 2022
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/verrica-pharmaceuticals-inc-loss-submission-form?prid=30494&wire=1

According to the filed complaint, during the class period, Verrica Pharmaceuticals, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) there were manufacturing deficiencies at the facility where Verrica's contract manufacturer produced a bulk solution for the Company's lead product candidate, VP-102; (2) these deficiencies were not remediated when Verrica resubmitted its New Drug Application for VP-12 for molluscum; (3) the foregoing presented significant risks to Verrica obtaining regulatory approval of VP-102 for molluscum; and (4) as a result of the foregoing, defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Outset Medical, Inc. (NASDAQ:OM)

This lawsuit is on behalf of all persons or entities who purchased Outset Medical common stock between September 15, 2020, and June 13, 2022.
Lead Plaintiff Deadline : September 6, 2022
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/outset-medical-inc-information-request-form?prid=30494&wire=1

According to the filed complaint, (1) the Company's flagship product, Tablo Hemodialysis System ('Tablo'), would require an additional 510(k) application to be filed with The United States Food and Drug Administration ('FDA'), as defendants had 'continuously made improvements and updates to Tablo over time since its original clearance' (2) as a result, the Company could not conduct a human factors study on a cleared device in accordance with FDA protocols; (3) the Company's inability to conduct the human factors study subjected the Company to the likelihood of the FDA imposing a 'shipment hold' and marketing suspension, leaving the Company unable to sell Tablo for home use; and (4) as a result, defendants' positive statements about the Company's business, operations, and prospects were materially false and misleading and /or lacked a reasonable basis at all relevant times.

You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Eduard Korsinsky, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP